Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
EyePoint halves workforce and ends Phase III trial early after endpoint missÂ
The biotech is now hoping that duravyu will have more success in DME, with pivotal readouts expected late next year.
Read Full Article
Pharma Tech
Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics
Buying the UK-based biotech will add a siRNA drug candidate with high sales potential to Merck’s portfolio.
Read Full Article
Pharma Tech
Ambrose Healthcare fortifies rare disease pipeline on AM-Pharma takeoverÂ
Ambrose will now enter the race to debut a new medicine on the HPP market as the only approved therapy edges closer to key patent expiries.
Read Full Article
Pharma Tech
Roche’s Enspryng nets a second indication on FDA eye disease approvalÂ
Enspryng is the first drug suitable for at-home administration in TED, but analysts are lukewarm on its commercial potential.
Read Full Article
PharmaShots
Beyond Clinical Trials: AbbVie’s Julie Adams, Roger McIntyre, and Andrew Cutler on VRAYLAR’s Real-World Impact
Shots: Saurabh: Real-world evidence can reveal how a therapy performs beyond the controlled environment of clinical trials. What do the latest CReW BP-I and ProACt findings reveal about the effectiveness of VRAYLAR in everyday clinical practice?  Julie: The findings from these prospective real-world studies show that VRAYLAR (cariprazine) improves depressive symptoms, functioning, and quality of… The post Beyond Clinical Trials: AbbVie’s Julie Adams, Roger McIntyre, and Andrew Cutler on VRAYLAR’s Real-World Impact appeared first on PharmaShots.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
Pharma Tech
Oct 20, 2026, 10:37 AM
EyePoint halves workforce and ends Phase III trial early after endpoint missÂ
The biotech is now hoping that duravyu will have more success in DME, with pivotal readouts expected late next year.
Pharma Tech
Oct 20, 2026, 10:28 AM
Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics
Buying the UK-based biotech will add a siRNA drug candidate with high sales potential to Merck’s portfolio.
ET Pharma
Oct 20, 2026, 6:17 AM
HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion
The Chinese biotech will use its proprietary AI-driven drug-delivery platform to develop next-generation technologies aimed at improving how LNP-based drugs reach target tissues.
PharmaShots
Oct 20, 2026, 6:02 AM
GSK’s Jemperli (Dostarlimab) Approved in the US for MSI-H/dMMR Locally Advanced Rectal Cancer
Shots: Ref: Globenewswire |  Image: GSK | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post GSK’s Jemperli (Dostarlimab) Approved in the US for MSI-H/dMMR Locally Advanced Rectal Cancer appeared first on PharmaShots.
Pharma Tech
Oct 20, 2026, 6:00 AM
Ambrose Healthcare fortifies rare disease pipeline on AM-Pharma takeoverÂ
Ambrose will now enter the race to debut a new medicine on the HPP market as the only approved therapy edges closer to key patent expiries.
PharmaShots
Oct 20, 2026, 5:37 AM
EyePoint Reports Topline P-III (LUCIA) Trial Results of Duravyu (Vorolanib Intravitreal Insert) for Wet AMD
Shots: EyePoint reported that its second pivotal P-III (LUCIA) trial (n=475) evaluating Duravyu (vorolanib intravitreal insert; 2.7mg Q24W) vs on-label aflibercept (2mg Q8W) after 3 monthly loading doses in pts with wet AMD did not meet its 1EP of statistical non-inferiority in mean change in BCVA at blended Wks. 52 & 56, despite demonstrating visual… The post EyePoint Reports Topline P-III (LUCIA) Trial Results of Duravyu (Vorolanib Intravitreal Insert) for Wet AMD appeared first on PharmaShots.
News
Latest industry coverage
Google News
Oct 20, 2026, 9:00 PM
Big pharma stumbles in lupus race as safety doubts push latecomers to prove - CHOSUNBIZ - Chosunbiz
Big pharma stumbles in lupus race as safety doubts push latecomers to prove - CHOSUNBIZÂ Â Chosunbiz
Google News
Oct 20, 2026, 8:59 PM
ScionxBio Partners with Sanofi on Extended Exposure Versions of mRNA Candidates - Contract Pharma
ScionxBio Partners with Sanofi on Extended Exposure Versions of mRNA Candidates  Contract Pharma
Google News
Oct 20, 2026, 8:39 PM
Rapid Micro Biosystems to showcase Growth Direc... - Pluang
Rapid Micro Biosystems to showcase Growth Direc...  Pluang
Google News
Oct 20, 2026, 8:25 PM
A conference talk will assess AI for early mold detection using Rapid Micro Biosystems' system. - Stock Titan
A conference talk will assess AI for early mold detection using Rapid Micro Biosystems' system.  Stock Titan
Google News
Oct 20, 2026, 8:15 PM
Systech Launches New All-in-One Pharma Packaging and Serialization Stations - PR Newswire
Systech Launches New All-in-One Pharma Packaging and Serialization Stations  PR Newswire
Google News
Oct 20, 2026, 8:08 PM
Bullfrog AI at LD Micro: pharma deal validation drives growth - Investing.com
Bullfrog AI at LD Micro: pharma deal validation drives growth  Investing.com
Google News
Oct 20, 2026, 8:05 PM
Vertex Appoints Daniel Brennan to its Board of Directors - Business Wire
Vertex Appoints Daniel Brennan to its Board of Directors  Business Wire
Google News
Oct 20, 2026, 8:01 PM
Laxxon Medical to Participate in the Jefferies Global Healthcare Conference - Business Wire
Laxxon Medical to Participate in the Jefferies Global Healthcare Conference  Business Wire
Google News
Oct 20, 2026, 7:30 PM
OpenAI Bets on Accelerating Drug Development Timelines with Orchestra Bio - PharmTech.com
OpenAI Bets on Accelerating Drug Development Timelines with Orchestra Bio  PharmTech.com
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer